HIV预防性血浆替诺福韦浓度的特征分析:来自HIV暴露前预防临床试验的汇总参与者水平数据分析
该研究汇总了三项3期试验(iPrEx、VOICE、Partners PrEP)中每日口服或局部外用替诺福韦二吡呋酯的活跃组参与者数据(n=2950),利用非线性混合效应模型整合纵向替诺福韦药代动力学、HIV结局、个体风险评分及出生性别数据,估计保护性血浆替诺福韦浓度。结果显示约50%的个体被估计为依从,远低于自我报告的约90%;口服给药后,高风险女性估计的保护性替诺福韦谷浓度(45.8 ng/mL)显著高于高风险男性(16.1 ng/mL)和低风险个体(约7.5 ng/mL)。结论认为高风险女性需要更高水平的血浆替诺福韦才能获得HIV保护,若实现每日依从,所有人群的HIV保护率均超过90%。
要点
- 约50%的个体被估计为依从,与自我报告的约90%依从率存在差异。
- 口服给药后,高风险女性估计的保护性替诺福韦谷浓度为45.8 ng/mL,高于高风险男性的16.1 ng/mL和低风险个体的约7.5 ng/mL。
- 给药模拟表明高风险女性需要完全依从才能维持保护性浓度;若每日依从,所有人群HIV保护率均超过90%。
核心结论
- 研究建立了群体依从-药代动力学-风险-结局模型,结果表明高风险女性相比男性需要更高水平的血浆替诺福韦才能获得HIV保护。
- 若实现每日依从,所有人群的HIV保护率均超过90%。
研究设计与样本
- 汇总了iPrEx、VOICE和Partners PrEP三项3期试验中每日口服或局部外用替诺福韦二吡呋酯活跃组的参与者数据(n=2950)。
- 基于先前的安慰剂分析创建了个体特异性HIV感染风险评分(低风险和高风险)。
- 整合纵向替诺福韦药代动力学、HIV结局、个体风险评分及出生性别数据,使用非线性混合效应模型进行分析。
主要发现
- 约50%的个体被估计为依从,与自我报告的约90%依从率不同,且纵向依从模式间存在较大变异。
- 口服给药后,高风险女性估计的保护性替诺福韦谷浓度为45.8 ng/mL,高风险男性为16.1 ng/mL,低风险个体约为7.5 ng/mL。
- 给药模拟表明高风险女性需要完全依从才能维持保护性浓度。
- 若实现每日依从,所有人群的HIV保护率均超过90%。
关键数值与推荐
- 口服给药后,高风险女性估计的保护性替诺福韦谷浓度为45.8 ng/mL。
- 口服给药后,高风险男性估计的保护性替诺福韦谷浓度为16.1 ng/mL。
- 口服给药后,低风险个体估计的保护性替诺福韦谷浓度约为7.5 ng/mL。
- 约50%的个体被估计为依从,自我报告的依从率约为90%。
- 若实现每日依从,所有人群的HIV保护率均超过90%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daily dosing of tenofovir disoproxil fumarate, with or without emtricitabine, has high efficacy in preventing human immunodeficiency virus (HIV) infection when individuals are adherent. The target protective plasma concentration of tenofovir (TFV), however, is not fully understood. The aim of this study is to estimate the protective TFV plasma concentration. METHODS: Participant data from TFV-based daily oral and topical active arms of phase 3 trials (iPrEx, VOICE, and Partners PrEP) were pooled (n = 2950). Individual specific risk scores (low and high risk) of acquiring HIV, based on an earlier placebo analysis, were created. Longitudinal TFV pharmacokinetics (PK), HIV outcome, individual risk scores and the effect of sex at birth data were integrated and analyzed using non-linear mixed effects models. RESULTS: Around 50% of the individuals were estimated to be adherent, which differed from self-reported adherence (∼90%) and large variation between longitudinal adherence patterns were identified. Following oral administration, the estimated protective TFV trough concentration was substantially higher in high-risk females (45.8 ng/mL) compared with high-risk males (16.1 ng/mL) and to low-risk individuals (∼7.5 ng/mL). Dosing simulations indicated that high-risk women require full adherence to maintain protective levels. CONCLUSIONS: Using the largest PK-HIV outcome database to date, we developed a population adherence-PK-risk-outcome model. Our results indicate that high-risk females need higher levels of plasma TFV to achieve HIV protection compared with males. HIV protection exceeds 90% in all populations if daily adherence is achieved.
引用
- Garcia-Cremades M, Vučićević K, Hendrix CW, et al. Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Clin Infect Dis. 2022. PMID: 35474481. doi:10.1093/cid/ciac313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。